
Tilray Brands, Trulieve Cannabis, and Cronos Group are the three Cannabis stocks to watch today, according to MarketBeat’s stock screener tool. Cannabis stocks are shares of publicly traded companies involved in the cultivation, processing, distribution, or sale of cannabis and cannabis-related products. For stock market investors, these securities represent an opportunity to gain exposure to the cannabis industry, but they may also carry heightened risks due to regulatory uncertainty, market volatility, and evolving legal frameworks. These companies had the highest dollar trading volume of any Cannabis stocks within the last several days.
Tilray Brands (TLRY)
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Trulieve Cannabis (TRLV)
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery.
Read Our Latest Research Report on TRLV
Cronos Group (CRON)
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.
Read Our Latest Research Report on CRON
Featured Articles
- MarketBeat’s Top Five Stocks to Own in August 2026
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
